Page 3 - Hyderabad Based Hetero News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dr Reddy’s Laboratories (DRL) has applied for emergency use authorisation with the Indian drug regulator for Sputnik V vaccine. Earlier, DRL had indicated that it aimed to launch the vaccine in March itself if it gets the regulator s nod. It has lined up 250 million doses of the vaccine for Indian citizens (from manufacturing partners) over the next 12 months. The human adenoviral vector (flu virus)-based vaccine candidate is developed by Gamaleya National Research Institute of Epidemiology and Microbiology in Russia and was registered in that country in August last year. DRL will present the safety profile of the phase 2 clinical study and the interim data of the phase 3 study which is expected to be completed by February 21, the company said.

Andhra pradeshDeepak sapraGamaleya national research institute of epidemiologySerum institute of indiaGamaleya national research instituteDrugs controller generalRussian direct invesHyderabad based heteroSerum instituteDr reddy amp rsquos laboratoriesCoronavirus vaccineCovid 19India pharma companiesHealthcare sectorஆந்திரா பிரதேஷ்தீபக் சப்ரா